Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Gross Profit
Aquestive Therapeutics Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Gross Profit
$31m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Aquestive Therapeutics Inc's Gross Profit?
Gross Profit
31m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Gross Profit amounts to 31m USD.
What is Aquestive Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
-4%
Over the last year, the Gross Profit growth was 16%. The average annual Gross Profit growth rates for Aquestive Therapeutics Inc have been -5% over the past three years , -4% over the past five years .